视频原文：Can a keto diet eliminate cancer growth? Dr. Thomas Seyfried says yes | TARGET: Cancer Podcast | Ep. 42
发表日期：2023年6月
嘉宾：托马斯·赛弗里德 博士 （Dr. Thomas Seyfried）
主持人：圣杰·朱尼贾 博士
视频原址：youtube.com/watch?v=qa3j40c8iAo
在这一集中，托马斯·赛弗里德博士讨论了癌症的代谢方法。了解如何通过剥夺癌细胞可发酵燃料（如葡萄糖和谷氨酰胺）来使其饥饿和死亡。挑战遗传疾病模型，探讨酮症对线粒体健康的影响。揭示癌症作为代谢性而非遗传性疾病的真相。通过代谢策略赋予自己抗击癌症的知识，了解围绕我们的危险：加工食品。
– – – -时间戳 – – – –
- 00:00 介绍
- 01:16 肿瘤的能量来源是什么？
- 06:46 生酮
- 12:06 压脉策略
- 18:07 饮食和生活方式
- 25:40 加工食品
- 36:31 糖酮指数
— 关于托马斯·赛弗里德博士 —
托马斯·N·赛弗里德是波士顿学院生物学教授，于1976年从伊利诺伊大学香槟分校获得遗传学和生物化学博士学位。他还在伊利诺伊州立大学获得遗传学硕士学位。在越战期间，托马斯·赛弗里德博士在美国陆军第一骑兵师表现卓越，并获得多个奖章和嘉奖。他曾在耶鲁大学医学院神经科学系担任博士后研究员，并在该系任教。他是多个期刊的编辑委员会成员，包括《营养与代谢》、《神经化学研究》、《脂质研究杂志》、《营养前沿》、《肿瘤前沿》和《ASN神经》，在后者担任高级编辑。赛弗里德博士有超过190篇同行评议的出版物，是书籍《癌症作为代谢性疾病：关于癌症的起源、管理和预防》（Wiley Press）的作者。他的书最近被翻译成中文，他的同行评议出版物完整列表可在PubMed上找到。
— 关于圣杰·朱尼贾博士 —
圣杰·朱尼贾博士是一位三板认证的血液学家和医学肿瘤学家，担任巴吞鲁日综合医院肿瘤服务主任，是一个在社交媒体上被称为“TheOncDoc”的社交媒体名人，拥有超过50万的关注者，是15位参与白宫社交媒体领导者圆桌系列的社交媒体医生之一。
他曾被《华盛顿邮报》以及数十家全国性播客和地区新闻频道（PBS、CBS、NBC、NPR）报道，并在美国癌症协会、BeTheMatch、白血病和淋巴瘤协会、哈佛大学、路易斯安那卫生署等机构进行主题演讲并合作。
— 关于xCURES —
xCURES平台是一个直接面向患者和医生的门户，为不对标准治疗产生响应的晚期癌症患者确定最有希望的治疗选项。
In this episode, Dr. Thomas Seyfried discusses metabolic approaches to cancer. Learn how depriving cancer cells of fermentable fuels like glucose and glutamine can starve and kill them. Challenge the genetic disease model and discover the impact of ketosis on mitochondrial health. Uncover the truth about cancer as a metabolic, not genetic, disease. Empower yourself with the knowledge to combat cancer through metabolic strategies and learn about the dangers surrounding us: processed foods.
– – – -TimeStamps – – – –
- 00:00 Introduction
- 01:16 What fuels the tumor?
- 06:46 Ketosis
- 12:06 The press pulse strategy
- 18:07 Diet and lifestyle
- 25:40 Processed foods
- 36:31 Glucose Ketone Index
– – – –
#cancertreatment #ketodiet #DrThomasSeyfried #ketosis #cancermetabolism
🔴Like, Subscribe, and Share to see more of this type of content!
— ABOUT DR. THOMAS SEYFRIED —
Thomas N. Seyfried is Professor of Biology at Boston College, and received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He also holds a Master’s degree in Genetics from Illinois State University, Normal, IL. Thomas Seyfried served with distinction in the United States Army’s First Cavalry Division during the Vietnam War, and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and served on the faculty. He serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, Frontiers in Nutrition, Frontiers in Oncology, and ASN Neuro, where his is a Senior Editor. Dr. Seyfried has over 190 peer-reviewed publications and is author of the book, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press). His book was recently translated into Chinese, and his full list of peer-reviewed publications can be found on PubMed.
— ABOUT DR. SANJAY JUNEJA —
Dr. Sanjay Juneja is a triple board-certified Hematologist & Medical Oncologist serving as Chief of Oncology Service at Baton Rouge General Hospital, a social & news media personality known as the ‘TheOncDoc’ with over half a million followers, and one of fifteen social media doctors participating in the Healthcare Leaders in Social Media Round Table Series for the White House.
He has been featured by The Washington Post as well as dozens of national podcasts and regional news channels (PBS, CBS, NBC, NPR), and has given keynote speeches and partnered with American Cancer Society, BeTheMatch, Leukemia & Lymphoma Society, Harvard University, Louisiana Department of Health and several others.
— ABOUT xCURES —
The xCures platform is a direct-to-patient and direct-to-physician portal that identifies the most promising treatment options for advanced cancer patients who are not responding to standard of care therapies.
The platform captures data that also helps accelerate the development of promising new cancer drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement.
